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ABSTRACT
A compendium of carcinogenesi s bioassay results organized by target organ is presented for 738 chemicals that are carcinogenic in chronic-exposure ,
long-term bioassays in at least 1 species. This compendium is based primarily on experiments in rats or mice; results in hamsters, monkeys, and dogs
are also reported. The compendium can be used to identify chemicals that induce tumors at particular sites and to determine whether target sites are
the same for chemicals positive in more than 1 species. The source of information is the Carcinogenic Potency Database (CPDB), which includes
results of 6073 experiments on 1458 chemicals (positive or negative for carcinogenicity) that have been reported in Technical Reports of the National
Cancer Institute/National Toxicology Program or in papers in the general published literature. The published CPDB includes detailed analyses of each
test and citations. The CPDB is publicly available in several formats (http://potency.berkeley.edu). Chemical carcinogens are reported for 35 different
target organs in rats or mice. Target organs in humans are also summarized for 82 agents that have been evaluated as human carcinogens at a particular
target site by the International Agency for Research on Cancer (IARC). Comparisons are provided of target organs for mutagens versus nonmutagens
and rats versus mice.
Keywords. Human carcinogen; tumor site; animal cancer test; Carcinogenic Potency Database; species comparisons; mutagenicity; monkeys.
INTRODUCTION
For many research issues in carcinogenesis, it is valuable
to have quick access to a list of chemicals that have been found
in chronic bioassays to induce tumors at each target site in
various species. Researchers interested in carcinogenesis in a
particular target organ, for example, or epidemiologists inter-
ested in a particular cancer in humans, can use such results to
compare species or seek clues in animal models. Comparison
of target sites in several species is possible for work on in-
terspecies extrapolation. Investigations of chemical structure
or mechanism of carcinogenesis at a speci c target site can
identify chemicals that induce tumors in that organ.
This paper presents a compendium of results of chronic,
long-term cancer tests that is organized by the target or-
gan of carcinogenesis (Table 1). Results are presented for
738 chemicals that have been evaluated by the published
author of experimental data as carcinogenic in at least one
experiment in the Carcinogenic Potency Database (CPDB)
(2, 3, 6), http://potency.berkeley.edu/database.html. Results
are organized by each of 35 target sites and within each
Address correspondenc e to: Lois Swirsky Gold, Mail Stop 946, E. O.
Lawrence Berkeley National Laboratory, Berkeley, California 94720. Fax:
(510) 547-7073. E-mail: lois@potency.berkeley.edu
site by the chemicals that induce tumors in each species.
The compendium includes results of chronic bioassays in
rats, mice, hamsters, monkeys, and dogs. Comparative tox-
icological analyses are facilitated by indicating whether a
chemical that is positive at a given site in the rat has been
tested in the mouse, whether results are also positive in
the mouse, and whether the target organs are the same in
the 2 species. By cross-referencing a chemical of interest to
the published plots of the CPDB (2, 3, 6), details of each
experiment can be obtained, including the number of ex-
periments and strains tested as well as the following details
on each experiment: citation of the original published paper,
strain and sex of test animal, route of chemical administra-
tion, dose rate, tumor types, tumor incidence, the tumorigenic
potency (TD50), statistical signi cance, and author’s opinion.
Target organs in humans are also summarized for 82 agents
that have been evaluated as human carcinogens at a particular
target site by the International Agency for Research on Cancer
(IARC) (10, 15, 16). Comparisons of target organs for muta-
gens versus nonmutagens, and for rats versus mice are also
provided.
METHODS
The CPDB (2, 3, 6), a systematic and unifying analysis
of chronic, long-term animal cancer tests, is the source of
639 0192-6233/01$3.00 $0.00
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results included in the compendium (Table 1). The CPDB
includes 1,381 papers published in the general literature
through 1996 and 430 Technical Reports of the National
Cancer Institute/National Toxicology Program (NCI/NTP)
published through 1998. Results are reported for 6,073 ex-
periments on 1,458 chemicals, of which 738 induce tumors
in 1 or more experiments.
A word of caution is necessary about the limitations of
the CPDB. Only long-term experiments meeting a set of cri-
teria designed to measure tumorigenic dose-rate (TD50) are
included; therefore, the CPDB does not cover all cancer tests.
Additionally, for the identi cation of target sites for the com-
pendium, we do not personally evaluate whether a compound
induced tumors at a given site; rather, the opinion of the pub-
lished author is used. For published opinions that are not
clear, even after personal communication with the published
author, the site is not considered a target and is not reported
in the compendium.
Results of all NCI/NTP Technical Reports are included in
the CPDB except a few, for which no whole body exposure in
mg/kg/day could be calculated because the test agent was a
particulate or the route of administration was dermal (12, 13)
[http://ntp-server.niehs.nih.gov/]. In the compendium, a site
is classi ed as a target in an NCI/NTP bioassay if the eval-
uation in the Technical Report was “carcinogenic,” “clear,”
or “some” evidence of carcinogenic activity. Sites that were
evaluated as “equivocal” are not included (9).
In the general literature, experimental designs as well as
the authors’ choice of information to report are quite diverse,
and bioassays have been included only if they meet all of the
following conditions:
1. Animals on test were mammals.
2. Administration was begun early in life (100 days of age
or less for rats, mice, and hamsters).
3. Route of administration was diet, water, gavage, inhala-
tion, intravenous or intraperitoneal injection (ie, where
the whole body was more likely to have been exposed
rather than only a speci c site, as with subcutaneous in-
jection or skin painting).
4. Test agent was administered alone, rather than in combi-
nation with other chemicals.
5. Exposure was chronic, with not more than 7 days between
administrations.
6. Duration of exposure was at least one fourth the standard
life span for that species. For rodents the standard life
span is 2 years.
7. Duration of experiment was at least half the standard life
span for that species.
8. Research design included a concurrent control group.
9. Research design included at least 5 animals per group.
10. Surgical intervention was not performed.
11. Pathology data were reported for the number of animals
with tumors rather than the total number of tumors.
12. Results reported were original data, rather than sec-
ondary analyses of experiments already reported by other
authors.
More details on inclusion criteria can be found in Gold
and coworkers (6) and http://potency.berkeley.edu/text/
methods.html.
Because we have adhered strictly to the standard inclu-
sion criteria, bioassays of particulate or  brous matters are
not in the compendium, eg, asbestos, cigarette smoke, and
dusts. There are no studies using a single administration of
the test agent, no experiments by skin painting, subcutaneous
injection, or in utero exposure, and no cocarcinogenesis ex-
periments. For a series of NCI long-term studies in monkeys,
some of the inclusion rules have been relaxed; details are
reported in Appendix 1 of Gold et al, 1999 (2).
There is great diversity in results for different chemicals
in the CPDB, eg, in the number of times a chemical has been
tested: among the 1,148 chemicals tested in rats, 25% have
only 1 test in the CPDB and 50% have 2 tests; however,
25 chemicals have 10 or more tests. For the 938 chemicals
tested in mice, the parallel numbers are 11% with 1 test, 57%
with 2 tests, and 15 chemicals with more than 10 tests. Of
the 738 carcinogens reported here, 54% (397/738) have been
tested in more than 1 species. In the compendium (Table 1),
a target site is identi ed by a positive result in any one ex-
periment in the species; thus, different target sites may be
identi ed from the same or different experiments. Chemi-
cals that are tested more often have a greater chance of  nd-
ing multiple target sites. Results on chemicals that have not
been evaluated as carcinogenic are ignored in the target or-
gan compendium (Table 1); however, detailed results of those
experiments are reported in the plot of the CPDB (2, 3, 6);
http://potency.berkeley.edu/.
Guide to the Compendium of Target Organs for 738
Carcinogens
Table 1 reports results on 738 chemicals in the CPDB that
induce tumors in at least 1 of 35 target organs in rats, mice,
hamsters, monkeys, or dogs. The table is organized alpha-
betically by target site and within each site, by species and
chemical. Our previously unpublished analyses of experi-
mental results that will be published in a forthcoming plot of
the CPDB are included (3).
To facilitate use of the compendium, the features are
described below using the example of adrenal gland, which
is the  rst of 35 target sites in Table 1. Under adrenal gland,
1 chemical is listed in hamsters, 8 in mice, and 16 in rats.
If a chemical name is followed by a superscript (either y
or z), this indicates that the CPDB includes test results in
both rats and mice, for example, under adrenal gland in rats
2-mercaptobenzothiazole but not isomazole, has a super-
script. Because isomazole has no superscript, it only has
tests in the CPDB in the species reported, in this case rats.
The superscript y for 2-mercaptobenzothiazole, indicates
that the chemical has been tested in both rats and mice but
induced tumors only in the reported species, in this case rats.
The superscript z for 1,2-dibromo-3-chloropropane (DBCP)
indicates that DBCP is carcinogenic at some target site in
both rats and mice. Although the superscript z does not indi-
cate whether DBCP induced tumors at the same target site in
both rats and mice, this can easily be determined by looking
at mice under adrenal gland for the chemical name DBCP.
Because it is not there, DBCP induced tumors in mice only at
sites other than the adrenal gland. In contrast,
pentachloroanisole z induced adrenal tumors in both species,
beacuse it is listed under that site for both species. By















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Vol. 29, No. 6, 2001 TARGET ORGANS OF CARCINOGENESIS 649
species, the reader can determine that pentachloroanisole is
the only chemical that induced adrenal tumors in both rats and
mice. The superscripts y and z apply only to results in rats and
mice; for example, hamsters are reported under adrenal gland
for urethane with the symbol z, indicating that urethane was
positive at some site in rats and mice; however, the superscript
does not indicate anything about hamsters.
RESULTS IN RATS AND MICE
For rats and mice, Table 2 summarizes the proportion
of carcinogens that are positive at each target organ, based
on the results presented in the compendium (Table 1). In
Table 2, the target sites are ordered by how frequently the
site is positive in either rats or mice. A summary of the com-
pendium is given under the headings “All Chemicals” for
rats (N 526) and mice (N 412). Additionally, for the
subset of carcinogens that have been tested in Salmonella
(N 459), results in each species are reported separately
for mutagens and nonmutagens. A chemical is classi ed as
mutagenic in the Salmonella assay if it was evaluated as ei-
ther “mutagenic” or “weakly mutagenic” by Zeiger (17) or as
“positive” by the Gene-Tox Program (11, 14) and A. Auletta
(personal communication April 1990). This summary table
permits simple comparisons between species and between
mutagens and nonmutagens.
TABLE 2.—Frequency of target organs by mutagenicity in Salmonella for 526 carcinogens in rats and 412 carcinogens in mice in the Carcinogenic Potency Database.
Chemicals evaluated as carcinogenic in:
Rats Mice
All chemicalsa Mutagens Nonmutagens All chemicalsa Mutagens Nonmutagens
Target organ (N 526)b (N 214) (N 126) (N 412) (N 176) (N 126)
Liver 206 (39%) 84 (39%) 40 (32%) 231 (56%) 92 (52%) 90 (71%)
Lung 55 (10%) 31 (14%) 3 (2%) 116 (28%) 54 (31%) 23 (18%)
Mammary gland 102 (19%) 60 (28%) 13 (10%) 24 (6%) 11 (6%) 8 (6%)
Kidney 86 (16%) 31 (14%) 36 (29%) 26 (6%) 12 (7%) 10 (8%)
Stomach 85 (16%) 45 (21%) 10 (8%) 63 (15%) 34 (19%) 14 (11%)
Vascular system 32 (6%) 18 (8%) 2 (2%) 59 (14%) 34 (19%) 11 (9%)
Hematopoietic system 56 (11%) 29 (14%) 16 (13%) 53 (13%) 23 (13%) 17 (13%)
Urinary bladder 49 (9%) 25 (12%) 14 (11%) 12 (3%) 8 (5%) 1
Nasal cavity/turbinates 43 (8%) 19 (9%) 6 (5%) 6 (1%) 6 (3%)
Ear/Zymbal’s gland 41 (8%) 31 (14%) 1 3 1 2 (2%)
Esophagus 36 (7%) 14 (7%) 1 8 (2%) 5 (3%) 1
Skin 33 (6%) 23 (11%) 3 (2%) 5 (1%) 4 (2%)
Thyroid gland 33 (6%) 14 (7%) 12 (10%) 18 (4%) 9 (5%) 9 (7%)
Oral cavity 32 (6%) 18 (8%) 6 (5%) 3 2 (1%) 1
Large intestine 32 (6%) 22 (10%) 1 1
Small intestine 29 (6%) 20 (9%) 2 (2%) 6 (1%) 4 (2%) 1
Uterus 26 (5%) 11 (5%) 6 (5%) 12 (3%) 8 (5%) 3 (2%)
Peritoneal cavity 22 (4%) 13 (6%) 5 (4%) 8 (2%) 2 (1%) 1
Pancreas 22 (4%) 8 (4%) 7 (6%)
Central nervous system 21 (4%) 14 (7%) 2 (2%) 3 2 (1%) 1
Harderian gland 19 (5%) 9 (5%) 7 (6%)
Clitoral/preputial gland 21 (4%) 16 (7%) 4 (3%) 11 (3%) 3 (2%) 2 (2%)
Testis 18 (3%) 7 (3%) 4 (3%) 4 2 (2%)
Adrenal gland 16 (3%) 7 (3%) 6 (5%) 8 (2%) 3 (2%) 5 (4%)
Subcutaneous tissue 13 (2%) 11 (5%) 1 4 3 (2%)
Ovary 10 (2%) 4 (2%) 5 (4%)
Pituitary gland 7 (1%) 2 4 (3%) 8 (2%) 2 (1%) 3 (2%)
Spleen 7 (1%) 4 (2%) 2 (2%)
Bone 5 2 1
Prostate 4 1 1
Gall bladder 4
Vagina 2 2 1 1
Myocardium 2 1
Mesovarium 2
a In the CPDB, 722 chemicals are carcinogenic in rats and/or mice, but mutagenicity in Salmonella is known for only 459 of them. The column “All chemicals” reports results for all
carcinogens in each species, whether mutagenicity results are available or not.
b% Percentage of rat carcinogens or mouse carcinogens that induce tumors at the given site. Many chemicals induce tumors at more than 1 site, and these are counted at each relevant
target site. Therefore, many chemicals are counted more than once, and percentages cannot be added. For example, of 206 chemicals that induce liver tumors in rats, 126 (61%) are positive
in at least one other site in rats.
All Carcinogens in Rats or Mice
Among rodent carcinogens, it is common for a chemical
to induce tumors at more than one site in a species, and this
is re ected in Table 2 where many chemicals are counted un-
der more than one site. Multiple-site carcinogenesis is more
common in rats (52%, 247/471) than mice (45%, 171/384),
with 3 or more target sites also more common in rats (31%,
148/471 compared to 19%, 72/384 in mice). Fewer chemi-
cals are included in the multiple-site analysis than the totals
in Table 2 because multiple-site carcinogenesis cannot be
measured for experiments that restrict histopathological ex-
amination or report data for only a couple of selected tissues.
Results are similar when experiments with restricted analyses
are included.
The liver is the most frequent target site in mice (56%) and
rats (39%) (Table 2). The second most common sites are the
mouse lung (28%) and the rat mammary gland (19%). Among
the 44 carcinogens in hamsters, the most frequent sites are
stomach and liver. For the 11 carcinogens in monkeys, liver
is the most frequent target site.
Despite the wide variety of target organs in rats and mice
(Tables 1 and 2), due to (a) the frequency of multiple-site
carcinogenesis and (b) the frequency of tumorigenesis in a
few common sites like liver, most chemical carcinogens in
rats and mice can be identi ed by just the 8 most common
650 GOLD ET AL TOXICOLOGIC PATHOLOGY
TABLE 3.—Target organs in humans for 82 agents evaluated as human carcinogens by the International Agency for Research on Cancer (10, 15, 16).
Target site Agent, mixture or industrial process
Anogenital Human papilloma virus 16
Bladder Aluminum production; 4-Aminobiphenyla ; Analgesic mixtures containing phenacetind ; Auramine manufactured ,e ;
Benzidinea ; N ,N -Bis(2-chloroethyl)-2-naphthylamine (chlornaphazine); Coal gasi cation; Coal-tar pitches;
Cyclophosphamidea ; Magenta manufactured ,e; 2-Naphthylaminea ,b ; Rubber industry; Schistosoma hematobium (infection);
Tobacco smoke
Bone Plutonium-239 and its decay products (may contain plutonium-240 and other isotopes), as aerosols; Radium-224
and its decay products; Radium-226 and its decay products; Radium-228 and its decay products
Brain Vinyl chloride a
Breast Diethylstilbestrola ; Estrogens, nonsteroidala ,e ; Estrogens, postmenopausa l therapyd ,e ; X-rays and c -rays
Cervix Human papilloma virus 16; Human papilloma virus 18
Cervix/vagina Diethylstilbestrola ; Estrogens, nonsteroidala ,e
Endometrium Estrogens, steroidala,e; Estrogens, postmenopausa l therapyd ,e; Oral contraceptives, sequential; Tamoxifena
Esophagus Alcoholic beveragesd ; Tobacco smoke
Gastrointestinal tract Asbestos
Hematopoietic system
Leukemia Benzenea ; Boot and shoe manufacture and repair; 1,4-Butanediol dimethanesulphonat e (Myleran)c; Chlorambucila ;
1-(2-(Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (methyl-CCNU); Cyclophosphamidea ; Etoposide in combination
with cisplatin and bleomycin; Melphalana ; MOPP and other combined chemotherapy including alkylating agents;
Phosphorus-32 , as phosphate; Rubber industry; Thio-tepaa ; Thorium-232 and its decay products, administered intravenously as
a colloidal dispersion of thorium-232 dioxide; Treosulfan; X-rays and c -rays
Lymphoma Azathioprinea ; Cyclosporinc ; Epstein-Barr virus; Human immunode ciency virus type 1 (HIV-1); Human T-cell
lymphotropic virus type I (HTLV-I); Vinyl chloridea
Hodgkin’s disease Epstein-Barr virus
Kaposi’s sarcoma Human immunode ciency virus type 1 (HIV-1)
Kidney Coke production
Renal pelvis Analgesic mixtures containing phenacetin (renal pelvis/ureter)d ; Tobacco smoke
Liver A atoxinsa ,b ; Alcoholic beveragesd ; Hepatitis B virus (chronic infection); Hepatitis C virus (chronic infection);
Opisthorchis viverrini (infection); Oral contraceptives , combineda ,e ; Plutonium-239 and its decay products (may contain
plutonium-240 and other isotopes), as aerosols; Vinyl chloridea
Cholangiocarcinoma Opisthorchis viverrini (infection)
Hepatobiliary system Azathioprinea
Lung Aluminum production; Arsenic and arsenic compoundsa ; Asbestos; Beryllium and beryllium compoundsc;
Bis(chloromethyl)ethera and technical choromethyl methyl ethera ; Cadmium and cadmium compoundsa ;
Chromium (VI) compounds a ; Coal gasi cation; Coal-tar pitches; Coal-tars; Coke production; Mustard gas (sulphur mustard);
Hematite mining (underground), with exposure to radon; Iron and steel founding; Nickel compoundsc ;
Painter (occupationa l exposure); Plutonium-239 and its decay products (may contain plutonium-240 and other isotopes),
as aerosols; Radon-222 and its decay products; Silica, crystalline, in the form of quartz or cristobalite from occupationa l sources;
Soots; Strong inorganic acid mists containing sulfuric acid (occupationa l exposure); Talc containing asbestiform  bers;
Thorium-232 and its decay products, administered intravenously as a colloidal dispersion of thorium-232 dioxide; Tobacco smoke;
Vinyl chloridea
Mesenchymal tumors Azathioprinea
Nasal sinus Boot and shoe manufacture and repair; Furniture and cabinet making; Isopropanol manufacture (strong acid process);
Nickel compoundsc ; Wood dust
Nasopharynx Epstein-Barr virus; Salted  sh, Chinese-style
Paranasal sinus Wood dust
Oral cavity Alcoholic beveragesd ; Betel-quid with tobacco; Tobacco products, smokeless (chewing tobacco, oral snuff ); Tobacco smoke
Larynx Alcoholic beveragesd ; Asbestos; Mustard gas (sulphur mustard); Strong inorganic acid mists containing sulfuric acid
(occupationa l exposure); Tobacco smoke




Skin Arsenic and arsenic compoundsa ; Azathioprinea ; Coal gasi cation; Coal-tar pitches; Coal-tars; Coke production;
8-Methoxypsoralen (methoxsalen)a plus UV radiation; Mineral oils, untreated and mildly treated; Shale-oils; Solar
radiation; Soots
Melanoma Solar radiation
Stomach Helicobacter pylori (infection)
Testis Diethylstilbestrola ; Estrogens, nonsteroidala ,e
Thyroid Radioiodines, short-lived isotopes, including iodine-131, from atomic reactor accidents and nuclear weapons detonation
(exposure during childhood); X-rays and c -rays
IARC has evaluated an additional 5 agents as having an overall evaluation, “carcinogenic to humans” but all 5 lack an IARC evaluation of “suf cient evidence” of carcinogenicity to
humans: a -particle-emitting radionuclides , internally deposited; b -particle-emitting radionuclides , internally deposited; ethylene oxide; neutron radiation; and TCDD.
IARC has evaluated the evidence of carcinogenicity in animals as “suf cient” for these 40 human carcinogens .
aTissues are reported in Table 1 for rodent experiments in the CPDB.
bTissues reported in Table 1 for monkey experiments in the CPDB.
cExperiments are reported in the CPDB, but none are positive.
d For 5 chemicals, there are positive tests with target sites in the CPDB; however, for the agent or exposure circumstance evaluated by IARC as “carcinogenic to humans” there are no
tests in the CPDB: auramine-O, estradiol, ethyl alcohol, phenacetin, and rosaniline (Magenta I).
eFor 6 human carcinogens IARC considers the evidence of carcinogenicity in experimental animals as “suf cient” for some chemical constituent, but the group or exposure circumstance
is not evaluated as “suf cient” in animals: auramine manufacture ; estrogens, steroidal and nonsteroidal ; estrogens, postmenopausal therapy; magenta manufacture ; and oral contraceptives ,
combined.
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sites: liver, lung, mammary gland, stomach, vascular system,
kidney, hematopoietic system, and urinary bladder (7). Over-
all, 92% (354/384) of mouse carcinogens and 82% (388/471)
of rat carcinogens are positive in at least one of these 8 sites.
Mutagenicity and Target Site
Mutagens compared to nonmutagens are: (a) more likely to
be carcinogenic; (b) more likely to induce tumors at multiple
target sites; and (c) more likely to be carcinogenic in 2 species
(4, 5, 8).
Since tissue distribution and pharmacokinetics would not
be expected to differ systematically between mutagens and
nonmutagens, one would not expect systematic differences
in the particular organs in which tumors are induced (8).
Results in Table 2 do not support the idea that mutagens and
nonmutagens induce tumors in different target organs. Liver
is the most common site for both mutagens and nonmutagens;
most organs are target sites for both mutagens and nonmuta-
gens, and both mutagens and nonmutagens induce tumors in
a wide variety of sites. Moreover, the same sites tend to be the
most common sites for both: at least 81% of either mutagens
or nonmutagens are positive in each species in at least one of
the 8 most frequent target sites. We earlier compared results
for mutagens and nonmutagens in speci c tissues (18).
Target Organs of Human Carcinogens
To complement the compendium of target organs in car-
cinogenesis bioassays (Table 1), Table 3 reports the target
organs of carcinogenicity in humans for 82 agents that the
International Agency for Research in Cancer (IARC) evalu-
ates as human carcinogens at a particular target site (10, 15,
16), http://www.iarc.fr/. In addition to individual chemicals
such as those reported in Table 1 for bioassays, the agents that
IARC evaluates as human carcinogens include industrial pro-
cesses, therapeutic combinations, infectious agents, ionizing
radiation, and mixtures such as tobacco smoke.
In Table 3, footnotes indicate which chemicals are in-
cluded in the CPDB among the 82 IARC human carcino-
gens with human target sites. The reader can compare
positivity and target sites in humans, rodents and mon-
keys for human carcinogens by searching for a chem-
ical name in our table “Results by Chemical” on the
Web (http://potency.berkeley.edu/chemicalsummary.html) or
in our plot of the CPDB (http://potency.berkeley.edu/
database.html).
Among the 82 human carcinogens with target sites, IARC
considers 52 to have been adequately tested in experimen-
tal animals. Agents that have not been tested adequately are
mostly exposure circumstances like the workplace, or infec-
tious agents. Of the 52 that have been tested in animals, IARC
evaluates 12 as having “limited evidence” in animals and 40
as “suf cient evidence.” (The 40 include 6 agents for which
a chemical constituent has “suf cient evidence” even though
the group or exposure circumstance that is a human carcino-
gen, does not, e.g., auramine-O for auramine manufacture.)
The 40 agents with “suf cient evidence” in animals are indi-
cated in Table 3 by a “ ”. Thus, evidence of carcinogenicity
is “suf cient” in experimental animals for only 40/82 (49%)
of human carcinogens.
Ultimately, for purposes of investigating interspecies ex-
trapolation or the practice of risk assessment to humans from
bioassay data, one wants to know whether the large num-
ber (many hundreds) of chemicals that have been shown to
be carcinogenic in experimental animals would also be car-
cinogenic in humans. This question cannot be answered by
reversing the question, that is, by asking whether the small
number of chemicals that are carcinogenic to humans are also
carcinogenic in rodent bioassays. The reason for this is that
even if most human carcinogens were carcinogenic to exper-
imental animals, the converse does not necessarily follow, as
can be demonstrated by a simple probabilistic argument (1).
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